Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Latorzeff

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 8, 2025
Radiotherapy for penile cancers: 2025 updateGeneviève Loos, Alexandre Escande, Sabrina Aziez, et al.
Cancer Treatment Reviews|October 29, 2015
Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU)Paul Sargos, Stéphane Guerif, Igor Latorzeff, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 17, 2026
Erratum to "External beam radiotherapy for prostatic cancers: 2025 update" [Cancer Radiother 29 (2025) 104777]Igor Latorzeff, Alizée Camps-Maléa, Christophe Hennequin, et al.
European Urology Oncology|August 28, 2023
Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic ReviewJennifer Le Guevelou, Paul Sargos, Ludovic Ferretti, et al.
European Urology|March 15, 2024
Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07)Loig Vaugier, Cyrille Morvan, David Pasquier, et al.
Clinical and Translational Radiation Oncology|December 19, 2023
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancerIngrid Masson, Laurène Larriviere, Marc-André Mahé, et al.
Frontiers in Oncology|January 28, 2022
Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective StudyIngrid Masson, Martine Bellanger, Geneviève Perrocheau, et al.
Radiation Oncology (London, England)|February 9, 2019
Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study)Sophie Jacob, Jérémy Camilleri, Sylvie Derreumaux, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2018
Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized TrialRenaud de Crevoisier, Mohamed Amine Bayar, Pascal Pommier, et al.
BMC Cancer|April 18, 2015
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in FranceNadine Houédé, Philippe Beuzeboc, Sophie Gourgou, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 8, 2025
Radiotherapy for penile cancers: 2025 updateGeneviève Loos, Alexandre Escande, Sabrina Aziez, et al.
Cancer Treatment Reviews|October 29, 2015
Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU)Paul Sargos, Stéphane Guerif, Igor Latorzeff, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 17, 2026
Erratum to "External beam radiotherapy for prostatic cancers: 2025 update" [Cancer Radiother 29 (2025) 104777]Igor Latorzeff, Alizée Camps-Maléa, Christophe Hennequin, et al.
European Urology Oncology|August 28, 2023
Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic ReviewJennifer Le Guevelou, Paul Sargos, Ludovic Ferretti, et al.
European Urology|March 15, 2024
Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07)Loig Vaugier, Cyrille Morvan, David Pasquier, et al.
Clinical and Translational Radiation Oncology|December 19, 2023
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancerIngrid Masson, Laurène Larriviere, Marc-André Mahé, et al.
Frontiers in Oncology|January 28, 2022
Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective StudyIngrid Masson, Martine Bellanger, Geneviève Perrocheau, et al.
Radiation Oncology (London, England)|February 9, 2019
Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study)Sophie Jacob, Jérémy Camilleri, Sylvie Derreumaux, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2018
Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized TrialRenaud de Crevoisier, Mohamed Amine Bayar, Pascal Pommier, et al.
BMC Cancer|April 18, 2015
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in FranceNadine Houédé, Philippe Beuzeboc, Sophie Gourgou, et al.
Pageof 8